ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2026
Key Highlights
- ➤Q3 revenue rose 46.0% to $8.0 million year over year
- ➤Q3 net income reached $953,000, versus a $140,000 loss
- ➤Gross margin increased to 44.2%, up 130 basis points
- ➤Cash increased to $7.9 million; company terminated its At-The-Market offering
- ➤New $3 million credit line is expected to be signed during Q4 2026
Expert Statements
Timothy C. Fiori, Chief Financial Officer of ImmuCell
“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025”
Timothy C. Fiori, Chief Financial Officer of ImmuCell
“Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025.”
Timothy C. Fiori, Chief Financial Officer of ImmuCell
“Gross margin was 44.2% in the third quarter of 2026, which is 130 basis points higher than the third quarter of 2025 and reflects higher pricing and manufacturing execution partially offset by the previously discussed shift of certain product development expenses to costs of goods sold.”
Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing of ImmuCell
“We are pleased with our third quarter revenue and with distributor out-the-door volume growth of 18% over 2025.”
Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing of ImmuCell
“Growth remained broad-based across our sales territories and product lines, supported by an increase in sales activity and continued progress in customer acquisition.”
Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing of ImmuCell
“We are also encouraged by inventory levels heading into our peak season as we shift our focus to the cow-calf market.”
Olivier te Boekhorst, President and CEO of ImmuCell
“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions.”
Olivier te Boekhorst, President and CEO of ImmuCell
“Increased commercial activity was supported by increased output from the manufacturing team.”
Olivier te Boekhorst, President and CEO of ImmuCell
“We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”
Timothy C. Fiori, Chief Financial Officer of ImmuCell
“We have negotiated a new, larger $3 million line of credit with our bank, which we expect to sign during the fourth quarter of 2026.”
Timothy C. Fiori, Chief Financial Officer of ImmuCell
“Additionally, given our strong cash position, we have terminated our At-The-Market offering.”
PORTLAND, Maine, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended September 30, 2026.
“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. “Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025. Gross margin was 44.2% in the third quarter of 2026, which is 130 basis points higher than the third quarter of 2025 and reflects higher pricing and manufacturing execution partially offset by the previously discussed shift of certain product development expenses to costs of goods sold.”
Get started
Create a free account to read the full story.